Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab

Clinical trial NCT05319639 · RECRUITING

Trial details

NCT number: NCT05319639
Sponsor: Fujian Cancer Hospital
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Gastric Cancer Stage IV

Start date: 2023-02-16
Primary completion: 2024-10-31
Enrollment: 51

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.